Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-
暂无分享,去创建一个
T. Hirano | M. Hashimoto | W. Yamamoto | K. Ebina | M. Hirao | Y. Maeda | A. Kumanogoh | A. Onishi | K. Murata | T. Takeuchi | Keiichi Yamamoto | H. Amuro | K. Nagai | Y. Son | M. Katayama | R. Hara | S. Jinno
[1] A. Tomelleri,et al. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. , 2020, Seminars in arthritis and rheumatism.
[2] T. Mimori,et al. The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study , 2019, Rheumatology International.
[3] J. Raynauld,et al. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry , 2019, Arthritis Research & Therapy.
[4] H. Yoshikawa,et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study- , 2019, PloS one.
[5] H. Yoshikawa,et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study , 2019, Arthritis Research & Therapy.
[6] X. Mariette,et al. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study , 2019, Clinical Rheumatology.
[7] K. Aoyagi,et al. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study , 2019, Rheumatology.
[8] K. Ohmura,et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study , 2018, Arthritis Research & Therapy.
[9] M. Genovese,et al. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial , 2018, The Journal of Rheumatology.
[10] H. Yoshikawa,et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study- , 2018, PloS one.
[11] A. Barton,et al. Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.
[12] A. Ogata,et al. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period , 2018, Modern rheumatology.
[13] P. Sarzi-Puttini,et al. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry , 2017, Clinical Rheumatology.
[14] T. Takeuchi,et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study , 2017, RMD Open.
[15] M. Genovese,et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis , 2016, Annals of the rheumatic diseases.
[16] J. Kremer,et al. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry , 2016, Arthritis Research & Therapy.
[17] J. Jansen,et al. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. , 2016, Clinical therapeutics.
[18] Y. Kawahito. [Guidelines for the management of rheumatoid arthritis]. , 2016, Nihon rinsho. Japanese journal of clinical medicine.
[19] Marcus John Beasley,et al. Twelve‐Year Retention Rate of First‐Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real‐Life Data From a Local Registry , 2016, Arthritis care & research.
[20] M. Matucci-Cerinic,et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. , 2016, Seminars in arthritis and rheumatism.
[21] T. Takeuchi,et al. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis , 2016, Clinical Rheumatology.
[22] H. Bliddal,et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. , 2015, Rheumatology.
[23] C. Gabay,et al. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. , 2015, Rheumatology.
[24] J. Smolen,et al. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges , 2015, Nature Reviews Rheumatology.
[25] P. Meroni,et al. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. , 2014, Rheumatology.
[26] H. Olsson,et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab , 2013, Annals of the rheumatic diseases.
[27] M. Neurath,et al. How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy , 2013, Nature Medicine.
[28] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[29] J. Kremer,et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry , 2012, Annals of the rheumatic diseases.
[30] T. Spector,et al. Pain reporting at different body sites is explained by a single underlying genetic factor , 2010, Rheumatology.
[31] Tsutomu Takeuchi,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.
[32] N. Miyasaka,et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis , 2009, Modern rheumatology.
[33] C. Gabay,et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. , 2009, Arthritis and rheumatism.
[34] N. Miyasaka,et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis , 2007, Modern rheumatology.
[35] F. Wolfe,et al. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues , 2004, Annals of the rheumatic diseases.
[36] B. Hogan. Ten years on , 1991, Nature.
[37] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[38] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[39] M. Neovius,et al. Ten years with biologics: to whom do data on effectiveness and safety apply? , 2011, Rheumatology.
[40] I. Christensen,et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. , 2010, Arthritis and rheumatism.
[41] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[42] C. Werning. [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.